DekaBank Deutsche Girozentrale’s 4D Molecular Therapeutics FDMT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256K	Hold	30,000	–	–	﹤0.01%	947
2026 Q1	$261K	Hold	30,000	–	–	﹤0.01%	948
2025 Q4	$1.17M	Hold	30,000	–	–	﹤0.01%	846
2025 Q3	$1.16M	Hold	30,000	–	–	﹤0.01%	843
2025 Q2	$1.17M	Hold	30,000	–	–	﹤0.01%	831
2025 Q1	$1.08M	Hold	30,000	–	–	﹤0.01%	834
2024 Q4	$1.02M	Hold	30,000	–	–	﹤0.01%	872
2024 Q3	$1.08M	Hold	30,000	–	–	﹤0.01%	871
2024 Q2	$1.08M	Hold	30,000	–	–	﹤0.01%	862
2024 Q1	$1.08M	Sell	30,000 -16,000	-35%	-$408K	﹤0.01%	862
2023 Q4	$966K	Buy	+46,000	New	+$605K	﹤0.01%	905

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

DekaBank Deutsche Girozentrale's FDMT Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 30,000 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #947.

DekaBank Deutsche Girozentrale first reported a position in FDMT in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.17M in Q4 2025. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

DekaBank Deutsche Girozentrale held 30,000 shares of 4D Molecular Therapeutics worth $256K as of Q2 2026.
DekaBank Deutsche Girozentrale left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #947 holding.
DekaBank Deutsche Girozentrale first reported a position in 4D Molecular Therapeutics in Q4 2023 and has held it in 11 quarters since.
DekaBank Deutsche Girozentrale's 4D Molecular Therapeutics position peaked at $1.17M in Q4 2025.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.